Kazia Therapeutics Limited (KZIA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Kazia Therapeutics Limited (KZIA) is up 71.1% since the beginning of the year. At $12 per share, KZIA is trading 32.2% below its 52-week high of $17. Investors who bought $1,000 worth of KZIA shares 5 years ago would now be looking at an investment worth $24.

Kazia Therapeutics Limited (KZIA) has returned 71.12% so far this year and 211.90% over the past 12 months.

Based on dividend-adjusted daily data since Nov 24, 2017, KZIA's average daily return is +0.18%, while the average monthly return is +1.45%. At this rate, an investment would double in approximately 4.0 years.

Historically, 40% of months were positive and 60% were negative. The best month was Aug 2020 with a return of +109.6%, while the worst month was Dec 2024 at -65.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.

On a daily basis, KZIA closed higher 44% of trading days. The best single day was Jul 10, 2024 with a return of +248.0%, while the worst single day was Aug 1, 2022 at -47.1%.

Kazia Therapeutics Limited has an annualized alpha of 41.02%, beta of 0.74, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since November 27, 2017.

• This stock participated in 211.63% of S&P 500 Index downside but only 124.09% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

KZIA ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Kazia Therapeutics Limited (KZIA) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Kazia Therapeutics Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Kazia Therapeutics Limited was 99.58%, occurring on Apr 21, 2025. The portfolio has not yet recovered.

The current Kazia Therapeutics Limited drawdown is 98.40%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Kazia Therapeutics Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Kazia Therapeutics Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.